OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal

Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2015.00034
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Preparative Immunotherapy With Anti-Ox40 and Anti-Ctla4 Improves the Response to Chemotherapy

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2014English

The Efficacy Versus Toxicity Profile of Combination Virotherapy and TLR Immunotherapy Highlights the Danger of Administering TLR Agonists to Oncolytic Virus-Treated Mice

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2013English

Putting the Brakes on BTLA in T Cell–mediated Cancer Immunotherapy

Journal of Clinical Investigation
Medicine
2010English

Combination Immunotherapy for Melanoma

JAMA Oncology
Cancer ResearchOncology
2015English

The Future of Cancer Treatment: Immunomodulation, CARs and Combination Immunotherapy

Nature Reviews Clinical Oncology
Oncology
2016English

Triple Combination Immunotherapy With GVAX, Anti-Pd-1 Monoclonal Antibody, and Agonist Anti-Ox40 Monoclonal Antibody Is Highly Effective Against Murine Intracranial Glioma

OncoImmunology
OncologyAllergyImmunology
2019English

Novel Non-Nucleotidic STING Agonists for Cancer Immunotherapy

Future Medicinal Chemistry
Drug DiscoveryMolecular MedicinePharmacology
2018English

MS21.06 Immunotherapy - Sequence or Combination?

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Combination Immunotherapy of Squamous Cell Carcinoma of the Head and Neck

Archives of Otolaryngology–Head & Neck Surgery
2000English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy